Research programme: monoclonal antibody therapeutics - HaemaLogiX

Drug Profile

Research programme: monoclonal antibody therapeutics - HaemaLogiX

Alternative Names: IST-1458; LambdaMab; MDX-1458

Latest Information Update: 10 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune System Therapeutics; Medarex
  • Developer HaemaLogiX
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; POEMS syndrome

Most Recent Events

  • 10 Jul 2018 9244514- added deal and HE. Brief review done- updated intro, added DC: Antineoplastics to the thes term
  • 04 Jul 2018 HaemaLogiX and Takeda agree to co-develop therapeutics for the treatment of Multiple myeloma
  • 20 Aug 2015 Preclinical trials in Multiple myeloma in Australia (Parenteral) - (Haemalogix pipeline Aug 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top